ARTV Company Profile and Key Details
NASDAQ : ARTV
Artiva Biotherapeutics
$5.32
-0.2-3.62%
At Close 4:00 PMPrice Chart
Stock Price Today
Artiva Biotherapeutics, Inc. (ARTV) stock declined over -3.62%, trading at $5.32 on NASDAQ, down from the previous close of $5.52. The stock opened at $5.47, fluctuating between $5.20 and $5.70 in the recent session.
Stock Snapshot
5.52
Prev. Close
131.49M
Market Cap
5.2
Day Low
-1.55
P/E Ratio
-3.43
EPS (TTM)
N/A
Cash Flow per Share
5.47
Open
24.72M
Number of Shares
5.7
Day High
22.03%
Free Float in %
N/A
Book Value
89.4K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 20, 2026 | 5.40 | 5.70 | 5.20 | 5.32 | 89.08K |
| Mar 19, 2026 | 5.82 | 5.89 | 5.37 | 5.52 | 137.17K |
| Mar 18, 2026 | 6.19 | 6.33 | 5.63 | 5.80 | 229.74K |
| Mar 17, 2026 | 6.25 | 6.60 | 6.15 | 6.32 | 101.64K |
| Mar 16, 2026 | 6.25 | 6.65 | 6.10 | 6.18 | 103.08K |
| Mar 13, 2026 | 6.65 | 6.76 | 5.95 | 6.18 | 203.37K |
| Mar 12, 2026 | 7.01 | 7.55 | 6.70 | 6.75 | 382.47K |
| Mar 11, 2026 | 6.12 | 7.75 | 6.03 | 7.13 | 842.23K |
| Mar 10, 2026 | 5.72 | 6.16 | 5.65 | 6.08 | 143.7K |
| Mar 09, 2026 | 5.63 | 5.90 | 5.48 | 5.71 | 108.8K |
| Mar 06, 2026 | 5.50 | 5.90 | 5.50 | 5.74 | 140.02K |
| Mar 03, 2026 | 5.58 | 5.66 | 5.19 | 5.47 | 162.91K |
| Mar 02, 2026 | 5.47 | 5.78 | 5.24 | 5.77 | 260.23K |
| Feb 27, 2026 | 5.42 | 6.07 | 5.30 | 5.82 | 240.87K |
| Feb 26, 2026 | 5.00 | 5.60 | 4.89 | 5.45 | 192.39K |
| Feb 25, 2026 | 5.07 | 5.07 | 4.86 | 5.03 | 120.87K |
| Feb 24, 2026 | 4.75 | 5.15 | 4.72 | 5.02 | 125.31K |
| Feb 23, 2026 | 4.59 | 5.00 | 4.48 | 4.80 | 113.06K |
| Feb 20, 2026 | 4.53 | 4.69 | 4.44 | 4.68 | 129.58K |
| Feb 19, 2026 | 4.16 | 4.66 | 4.07 | 4.53 | 238.21K |
Contact Details
About Company
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Company Information
| Employees | 96 |
| Beta | 2.19 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
-4.58-0.62%
Regeneron Pharmaceuticals, Inc.$732.87ARGX-20.57-3.01%
argenx SE$663.93UTHR-2.72-0.52%
United Therapeutics Corporation$524.28VRTX-4.05-0.88%
Vertex Pharmaceuticals Incorporated$454.00MDGL-13.06-2.88%
Madrigal Pharmaceuticals, Inc.$441.16KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY1.07+0.34%
Alnylam Pharmaceuticals, Inc.$312.17PRAX0.81+0.27%
Praxis Precision Medicines, Inc.$298.31KRYS-6.32-2.45%
Krystal Biotech, Inc.$251.68SGEN-0.16-0.07%
Seagen Inc.$228.74Company Overview
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) closed at $5.32 USD, losing -$0.20 (-3.62%) from the previous close of $5.52. The stock is currently mid-range between its 52-week high and low $1.47 and $7.75. With a market capitalization of about $131.49 million, Artiva Biotherapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.19). Key stats such as the average daily volume over the past year has been around 187.59 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Artiva Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fred Aslan, the company employs approximately 96 people and listed since July 19, 2024. Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 27.46%, SMA50 22.05%, SMA200 68.67%). The stock’s 14-day RSI is 70.9 (overbought), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.95% below its high and over 270.75% above its low. Average 10-day trading volume of 144.01 thousand shares is below the 3-month average of 190.38 thousand, indicating normal recent market interest.
Dividend & Fair Value
Artiva Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.64. This means the shares are trading above this model’s fair value.
Shareholding & Insider Activity
Artiva Biotherapeutics, Inc. has 24.54 million shares outstanding. The public float is 4.06 million shares, elevated short interest at 1.91% of float. This equals 189.12 thousand shares. The short ratio is 1.07 days. Institutional investors hold 97.58% of the float. Insiders own 24.05%. venBio Global Strategic Fund III, L.P. holds 1.94 million shares, GC Corp. has 1.26 million shares and Huh Yong-Jun has 1.26 million shares. Over the past six months, insider transactions show net selling. They sold 35.06 thousand shares across 3 transactions.
Financial & Profitability Overview
On valuation metrics, Artiva Biotherapeutics trades at a P/E of -1.55, P/S of 0.00 and P/B of 1.18. The current ratio is 8.61 and quick ratio is 8.61. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -7.01.
Frequently Asked Questions
What is the current Artiva Biotherapeutics, Inc. (ARTV) stock price?
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) stock price is $5.32 in the last trading session. During the trading session, ARTV stock reached the peak price of $5.70 while $5.20 was the lowest point it dropped to. The percentage change in ARTV stock occurred in the recent session was -3.62% while the dollar amount for the price change in ARTV stock was - $0.20.
ARTV's industry and sector of operation?
The NASDAQ listed ARTV is part of Biotechnology industry that operates in the broader Healthcare sector. Artiva Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ARTV?
No Data
How ARTV did perform over past 52-week?
ARTV's closing price is 261.9% higher than its 52-week low of $1.47 where as its distance from 52-week high of $7.75 is -31.39%.
How many employees does ARTV have?
Number of ARTV employees currently stands at 96.
Link for ARTV official website?
Official Website of ARTV is: https://www.artivabio.com
How do I contact ARTV?
ARTV could be contacted at phone 858 267 4467 and can also be accessed through its website. ARTV operates from 5505 Morehouse Drive, San Diego, CA 92121, United States.
How many shares of ARTV are traded daily?
ARTV stock volume for the day was 89.4K shares. The average number of ARTV shares traded daily for last 3 months was 187.59K.
What is the market cap of ARTV currently?
The market value of ARTV currently stands at $131.49M with its latest stock price at $5.32 and 24.72M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep